Shortcut Navigation:

Breast Cancer News

In this section, access cutting-edge metastatic breast cancer news on treatment updates, emerging therapies, study results and other medical and quality-of-life issues important to you.

Novartis's Afinitor shows promise in breast cancer

STOCKHOLM (Reuters) - Combining two drugs from Novartis and Pfizer to treat post-menopausal women with a certain type of advanced breast cancer more than doubled the time they lived without their disease getting worse, study data showed on Monday.

Roche's pertuzumab helps breast cancer patients

ZURICH (Reuters) - Patients with advanced breast cancer lived significantly longer without their disease getting worse when treated with Roche's pertuzumab and Herceptin along with a type of chemotherapy, a late-stage study showed.

Novartis gets good news on cancer drug Afinitor

ZURICH (Reuters) - Novartis AG said a late-stage study showed its drug hope Afinitor slowed tumor growth in advanced breast cancer, helping its chances of becoming a new blockbuster treatment.

Medicare will keep covering Roche's Avastin

WASHINGTON (Reuters) - Medicare will continue coverage of Roche Holdings' drug Avastin for breast cancer regardless of what U.S. health regulators decide about the medicine, a spokesperson for the U.S. health insurer said.

Roche undeterred after FDA's Avastin rebuff

ZURICH (Reuters) - Swiss drugmaker Roche Holding AG had nothing to lose by giving Avastin another roll of the dice, and by doing so showed the world it still believes the drug should be used in breast cancer.

US FDA panel rejects Avastin for breast cancer use

SILVER SPRING, Md. (Reuters) - U.S. health advisers delivered a blow to Roche Holding on Wednesday, voting to reject the use of Roche Holding drug Avastin for breast cancer while the Swiss drugmaker conducts more studies.

FDA Invites Comments on Avastin

FDA officials have invited the public to testify at a hearing that will argue the merits of bevacizumab (Avastin) as an approved treatment for HER2 negative metastatic breast cancer.

NCCN Updates Metastatic Guidelines

The National Comprehensive Cancer Network’s updated clinical practice guidelines for metastatic breast cancer retain bevacizumab as a treatment option and add two new therapies, the chemotherapy medicine eribulin and the RANKL inhibitor denosumab.

FDA Grants Avastin Hearing

FDA has agreed to Genentech’s request to revisit the agency’s decision to withdraw bevacizumab (Avastin) as an approved treatment for HER2 negative metastatic breast cancer. A public hearing is scheduled for June 28-29, and the resultant ruling is final.

Company Requests Hearing for Avastin

Roche/Genentech, maker of Avastin (bevacizumab), has requested a hearing before the U.S. Food and Drug Administration to appeal the agency’s December 2010 decision to withdraw approval of bevacizumab as a treatment for metastatic breast cancer.

Denver, CO  ·  September 13, 2014

Join Your Community for Yoga on the Steps!

Close
close